Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Regulation FD DisclosureItem 7.01Regulation FD Disclosure.
On June 15, 2018, Blueprint Medicines Corporation (the “Company”) issued a press release announcing new data from its ongoing Phase 1 clinical trial evaluating avapritinib for the treatment of advanced systemic mastocytosis. The data will be presented on Friday, June 15, 2018 in a poster presentation at the 23rd Congress of the European Hematology Association in Stockholm, Sweden. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K, and a copy of the poster presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits.